Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LHsurges in women undergoing ovarian stimulation
Autore:
van Hooren, HG;
Indirizzi:
NV Organon, Clin Dev Dept, NL-5340 BH Oss, Netherlands NV Organon Oss Netherlands NL-5340 BH Dept, NL-5340 BH Oss, Netherlands
Titolo Testata:
HUMAN REPRODUCTION
fascicolo: 4, volume: 16, anno: 2001,
pagine: 644 - 651
SICI:
0268-1161(200104)16:4<644:CCOUTG>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
HORMONE-RELEASING HORMONE; HYPERSTIMULATION SYNDROME; LUTEINIZING-HORMONE; INVITRO FERTILIZATION; ASSISTED REPRODUCTION; PHASE; SUPPRESSION; MANAGEMENT; OVULATION; ANALOGS;
Keywords:
ganirelix; GnRH antagonist; ovarian stimulation; recombinant FSH; triptorelin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: van Hooren, HG NV Organon, Clin Dev Dept, POB 20, NL-5340 BH Oss, Netherlands NV Organon POB 20 Oss Netherlands NL-5340 BH , Netherlands
Citazione:
H.G. van Hooren, "Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LHsurges in women undergoing ovarian stimulation", HUM REPR, 16(4), 2001, pp. 644-651

Abstract

This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran(R), Antagon(TM)) treatment, usingtriptorelin (Decapeptyl(R)) in a long protocol as a reference treatment, In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg,s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1), Treatment with ganirelix started on day 6 of stimulation, whereas treatment with triptorelin started on menstrual cycle day 21 to 24 of the previous cycle (i.e. the midluteal phase). The ganirelix regimen was on average 17days shorter (9 versus 26 days) compared to the triptorelin regimen. The median total dose of recombinant FSH (Puregon(R)) used was 450 IU less (1350versus 1800 IU) in the ganirelix protocol. The initial follicular growth was faster and, consequently, oestradiol concentrations were higher in the ganirelix group. On the day of human chorionic gonadotrophin (HCG), the meannumber of follicles greater than or equal to 11 mm was 10.1 and 10.7 and the median serum oestradiol concentration was 1090 and 1370 pg/ml in the ganirelix and triptorelin groups respectively. Per attempt, 7.9 and 9.6 oocytes (mean) were retrieved in the ganirelix and triptorelin groups respectively. The fertilization rates (64.0% ganirelix and 64.9% triptorelin) and the mean number of good quality embryos (2.7 and 2.9) were comparable in both treatment groups. The implantation rate was identical (22.9%), The ongoing pregnancy rate per attempt was 31.0 and 33.9% in the ganirelix and triptorelin groups respectively. The ganirelix regimen showed an improved local tolerance in that the percentage of subjects with at least one local skin reaction was 2-fold lower than in the triptorelin group (11.9 versus 24.1%), Taking all data together, it may be concluded that ganirelix offers a new treatment regimen in ovarian stimulation that is short, safe and well-tolerated, optimizing convenience for the patient.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 18:15:36